Sunovion takes Urovant's overactive bladder med Gemtesa to primary care docs as promo partnership launches

A few months after Urovant's Gemtesa made its debut, Sunovion is joining the sales and marketing effort.

Urovant will continue to promote the overactive bladder drug to specialty and long-term care doctors, while Sunovion is taking the message to primary care physicians.